AGENDA OF 2022 EXTRAORDINARY AGMS
1. Approval of the Company's Capital Increase Plan by granting Pre-emptive Rights (PMHMETD) to shareholders who are entitled to subscribe for new Series B Shares offered in this PMHMETD or other equity securities in the form of Mandatory Convertible Debt Instruments or Mandatory Convertible Bonds (“OWK”) which within a certain period of time will be converted into new Series B Shares, as referred to in Financial Services Authority (OJK) Regulation No.32/POJK.04/2015 juncto the Financial Services Authority (OJK) Regulation No.14/POJK.04/2019.
With due observance to the provisions of Article 8 paragraph (3) of Financial Services Authority (OJK) Regulation No.32/POJK.04/2015 juncto Financial Services Authority (OJK) No.14/POJK.04/2019, the Company resubmits the PMHMETD plan to obtain approval for the Extraordinary General Meeting of Shareholders to be held on14 October 2022. The PMHMETD is planned to be carried out by issuing a maximum of 2,779,397,000 Series B shares. The PMHMETD plan has previously obtained approval from the Extraordinary General Meeting of Shareholders to be held on 18 August 2021, but there is an adjustment that will be offered to the shareholders of the Company which originally were Pre-emptive Rights (HMETD) to subscribe Mandatory Convertible Bond (MCB) to become HMETD to subscribe for new Series B shares or MCB, where each shareholder of the Company has the same and equal rights to exercise the Pre-emptive Rights which become their rights to purchase New Series B Shares or place an order of MCB.
Based on the provisions of Article 11 paragraph (10), Article 14 paragraph (12), Article 23 paragraph (6) letter b, and Article 25 paragraph (4) of the Company's Articles of Association, that the Board of Directors and Board of Commissioners are appointed and dismissed by the GMS.
Rules of Extraordinary GMS PT Kimia Farma Tbk Download